Board of Directors

Michael Ross

SV Health Investors

Joshua Resnick

SV Health Investors

Leon Chen

OrbiMed

Max Krummel, PhD

Robert E. Smith Endowed Chair in Experimental Pathology, UCSF

Steven P. James

Executive Chairman and CEO, Pionyr Immunotherapeutics


Michael Ross

SV Health Investors

Dr. Michael Ross joined SV Health Investors as a Venture Partner in 2001, became a Managing Partner in 2002 and is based in San Francisco.

Michael serves on the Thayer School of Engineering (Dartmouth College). He has also served on the boards of Carta Proteomics, Epimmune, Genencor, MetaXen, and Xenova. Michael was the tenth employee at Genentech where he worked for 13 years. He served as Genentech team leader for Humulin® (human insulin-Lilly), Roferon® (Interferon alpha -Roche), Protropin® (hGH), Vice President of Development during the development of Activase®, Nutropin® and Pulmozyme®. Michael then started Genentech’s protein engineering and small molecule discovery effort as Vice President of Medicinal and Biomolecular Chemistry. Michael was the Founding CEO of Arris Pharmaceutical, MetaXen, ExSAR and CyThera (now Novocell). Michael was also Managing Partner in Didyma, LLC, a biotechnology management consulting firm.

Michael received his AB from Dartmouth College, his PhD in Chemistry at Caltech, and completed a Post Doctorate in Molecular Biology at Harvard.

Joshua Resnick

SV Health Investors

Dr. Resnick is a highly-regarded life sciences leader, entrepreneur, and investment professional with more than 15 years of experience in investing, company formation, and company leadership across all stages from discovery through commercialization. Before joining SV Health Investors, Dr. Resnick was President and Managing Partner at MRL Ventures Fund, the early-stage therapeutics-focused corporate venture fund that he established, built and managed within Merck & Co. Prior to MRL Ventures, Dr. Resnick was a Venture Partner with Atlas Venture, focusing on company formation, seed and Series A investing. During his tenure at Atlas, Dr. Resnick was also the Founder and CEO of two start-ups in the immuno-oncology and neuro spaces. Prior to Atlas Venture, Dr. Resnick was a Partner at Prism Venture Partners, where he focused on early-stage biopharmaceutical, medical device, tools and diagnostics investments. Dr. Resnick is also an Attending Physician at Massachusetts General Hospital as well as Brigham and Women’s Hospital, and an Instructor in Medicine at Harvard Medical School.

Dr. Resnick graduated Magna Cum Laude from Williams College and received his MD and MBA from the University of Pennsylvania School of Medicine and Wharton School of Business. 

Leon Chen

OrbiMed

Leon Chen, Ph.D., is a Venture Partner with OrbiMed. Prior to joining OrbiMed, Dr. Chen was the co-founder of KAI Pharmaceuticals where he built the company as the first employee. He held responsibilities in research, intellectual property and business development before Amgen acquired KAI in 2012. He was previously an Entrepreneur in Residence at Venrock and most recently was a Partner at Skyline Ventures where he served on the board of a number of biotech and diagnostic companies. Dr. Chen has a B.A. in Biochemistry from U.C. Berkeley, a Ph.D in Molecular Pharmacology from Stanford and an M.B.A from the Stanford Graduate School of Business.

Max Krummel, PhD

Robert E. Smith Endowed Chair in Experimental Pathology, UCSF

Dr. Krummel is a Professor and the Robert E. Smith Endowed Chair in Experimental Pathology at UCSF. He studies mechanisms that regulate T cell response and immune function, using cutting-edge real-time imaging methods. As a graduate student, he developed expertise in the generation and use of monoclonal antibodies targeted to costimulatory and inhibitory molecules on T cells. He generated antibodies to CTLA-4, which identified an inhibitory pathway of T cell regulation and also could be used to trigger or block that pathway. This approach led to the development of human antibodies of the same type, a therapy now named ‘ipilimumab’, now FDA approved and widely used for treatment of melanoma and other cancers.

Dr. Krummel’s lab now focuses on figuring out how immune systems, collections of cells in complex tissues, work. The use of fluorescent proteins and real-time imaging enable the examination of information processing by the immune system. These approaches reveal how motile immune cells ‘search’ their environment for critical information and characterize specific phagocytes in the tumor microenvironments as primary players in transmitting signals to lymphocytes and regulating disease outcome.

Dr. Krummel earned his doctorate at UC Berkeley and did postdoctoral fellowships at Stanford University and the Walter and Eliza Hall Institute in Melbourne, Australia.

Steven P. James

Executive Chairman and CEO, Pionyr Immunotherapeutics

Steve has over 25 years of biopharma experience and has been involved in building and leading numerous companies. Prior to joining Pionyr in February 2016, he was president, CEO, and a director of Labrys Biologics until it was acquired by Teva Pharmaceuticals. Prior to Labrys, Steve was president, CEO, and a director of KAI Pharmaceuticals which was acquired by Amgen. He has held leadership positions at Exelixis, Sunesis Pharmaceutials, Ionis Pharmaceuticals, Landec Corporation, and Eli Lilly. He holds a Masters in Management from the Kellogg School of Northwestern University and an undergraduate degree in neuroscience from Brown University. Steve is currently a director of Ocera Inc., Cascadian Therapeutics, Antiva Biosciences, Allakos Inc., and Chrono Therapeutics and is a trustee of Middlebridge School in Rhode Island.